Eli Lilly and Company (NYSE:LLY) saw its stock rise in Tuesday premarket trading after the pharmaceutical firm reported encouraging results from a Phase 3 trial of its oral weight loss medication, clearing the path for global regulatory submissions later this year.
The ATTAIN-2 study demonstrated that orforglipron achieved its primary endpoint and all key secondary endpoints in adults with obesity or overweight who also have type 2 diabetes.
The once-daily oral drug also showed meaningful improvements in blood sugar management, with participants in the highest-dose group experiencing a 1.8% drop in A1C from a baseline of 8.1%.
Shares of Eli Lilly rose roughly 2% in premarket trading following the announcement.
Moreover, 75% of patients receiving the 36mg dose reached an A1C of 6.5% or below, which falls beneath the American Diabetes Association’s threshold for diabetes.
“With these positive data in hand, we are moving with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting,” said Kenneth Custer, Lilly executive vice president and president of Lilly Cardiometabolic Health.
The safety profile aligned with injectable GLP-1 treatments, with gastrointestinal side effects—such as nausea, vomiting, diarrhea, constipation, and dyspepsia—being the most common and generally mild-to-moderate in severity.
The completion of ATTAIN-2 equips Lilly with the comprehensive clinical data needed for worldwide regulatory filings for orforglipron, which can be taken without restrictions on food or water.
Lilly’s ATTAIN Phase 3 program has enrolled over 4,500 participants with obesity or overweight across two global registration trials.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.